NCT05497102View on ClinicalTrials.gov

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide maintenance

Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.

Trial Locations (1)

Unknown

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER